Alpha-1 Antitrypsin Deficiency (A1AD) (Genitourinary Disorders) - Drugs In Development, 2021

July 2021 | 138 pages | ID: AE10ECAF354BEN
Global Markets Direct

Abstracts

Alpha-1 Antitrypsin Deficiency (A1AD) (Genitourinary Disorders) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha-1 Antitrypsin Deficiency - Drugs In Development, 2021, provides an overview of the Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) pipeline landscape.Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha-1 Antitrypsin Deficiency - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 2, 19, 3 and 2 respectively.Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders).%li%The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.%li%The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.%li%The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) therapeutics and enlists all their major and minor projects.%li%The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.%li%The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.%li%Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.%li%Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders).%li%Classify potential new clients or partners in the target demographic.%li%Develop tactical initiatives by understanding the focus areas of leading companies.%li%Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.%li%Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (Genitourinary Disorders) pipeline depth and focus of Indication therapeutics.%li%Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.%li%Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Alpha-1 Antitrypsin Deficiency (A1AD) - Overview
Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Development
Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Assessment
Alpha-1 Antitrypsin Deficiency (A1AD) - Companies Involved in Therapeutics Development
Alpha-1 Antitrypsin Deficiency (A1AD) - Drug Profiles
Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects
Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products
Alpha-1 Antitrypsin Deficiency (A1AD) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Alnylam Pharmaceuticals Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Apic Bio Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Applied Genetic Technologies Corp, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Beam Therapeutics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Caravella Biopharma SA, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Centessa Pharmaceuticals Plc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Dicerna Pharmaceuticals Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Editas Medicine Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Evolve Biologics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Grifols SA, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Inhibrx Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Intellia Therapeutics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by International Stem Cell Corp, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Kamada Pharmaceuticals, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Krystal Biotech Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by LEXEO Therapeutics LLC, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Liminal BioSciences Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Logicbio Therapeutics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Mereo Biopharma Group Plc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Moderna Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by pH Pharma Co Ltd, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by PlantForm Corp, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Promethera Biosciences SA, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Renovion Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Santhera Pharmaceuticals Holding AG, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Shape Therapeutics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Vera Therapeutics Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Vertex Pharmaceuticals Inc, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Wave Life Sciences Ltd, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, 2021
Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, 2021 (Contd..1)
Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021